$ 6.93
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/E
Target Price
The average target price of BVS is 12 and suggests 76% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
